生物活性在神经退行性疾病中的作用
1Department of Health Sciences, School of Life and Health Sciences, University of Nicosia, 2417 Nicosia, Cyprus.
International journal of molecular sciences
|May 11, 2024
概括
数以百万计的人受到神经退行性疾病的影响,如阿尔茨海默氏症和帕金森病. 这项研究探讨了这些普遍的大脑疾病的关键方面.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 医学研究 医学研究
背景情况:
- 神经退行性疾病 (NDs) 构成了全球严重的健康负担.
- 阿尔茨海默病和帕金森病是最常见的NDs形式.
- 了解ND的潜在机制对于开发有效的治疗方法至关重要.
研究的目的:
- 总结目前对阿尔茨海默氏症和帕金森病的理解.
- 为了突出最近神经退行领域的进展.
- 为了确定NDs的潜在治疗目标.
主要方法:
- 对有关阿尔茨海默氏症和帕金森病的现有文献的综述.
- 对ND流行率的流行病学数据的分析.
- 从临床前和临床研究中得出的结合结果.
主要成果:
- 阿尔茨海默病的特点是粉样质斑块和神经纤维状结.
- 帕金森病涉及多巴胺能神经元和莱维体的丧失.
- 遗传和环境因素有助于发展NDs的风险.
结论:
- 早期诊断和干预对于管理NDs至关重要.
- 需要进一步的研究来开发疾病修饰疗法.
- 针对各种途径的多方面的方法对于对抗神经退行是必不可少的.
更多相关视频
07:57An Alternative Approach to Study Primary Events in Neurodegeneration Using Ex Vivo Rat Brain Slices
Published on: April 11, 2018
6.9K
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
10.6K
相关概念视频
Alzheimer's Disease: Overview
467
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
The Blood-brain Barrier
47.2K
Overview
47.2K
Role of Neurotransmitters in Memory
531
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
531
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
